Analyst Ratings January 27, 2026

Oppenheimer Lowers Roper Rating After Mixed Q4 and Tepid FY26 Outlook

Research firm moves rating to Perform and withdraws price target as persistent unit-level headwinds and cautious guidance weigh on investor confidence

By Leila Farooq ROP
Oppenheimer Lowers Roper Rating After Mixed Q4 and Tepid FY26 Outlook
ROP

Oppenheimer downgraded Roper Industries (NASDAQ:ROP) from Outperform to Perform and withdrew its price target following mixed fourth-quarter results and conservative fiscal 2026 guidance. The firm flagged ongoing challenges across several Roper business units, trimmed revenue and EPS forecasts, and said the company must show higher organic growth to regain a premium valuation.

Key Points

  • Oppenheimer moved Roper from Outperform to Perform and withdrew its price target after mixed Q4 results and weak fiscal 2026 guidance.
  • Persistent headwinds at Deltek, Procare, DAT, and Neptune were cited as central factors behind the downgrade.
  • Roper beat EPS estimates for Q4 2025 but missed revenue expectations; analysts are monitoring subsequent guidance and execution closely.

Oppenheimer announced a downgrade of Roper Industries (NASDAQ:ROP), moving the stock from Outperform to Perform and withdrawing its prior price target after the company released mixed fourth-quarter results and offered disappointing guidance for fiscal year 2026. The move follows a pronounced share-price slide; Roper has fallen 27.15% over the past six months.

The research house pointed to continued pressure across a number of Roper business units - specifically Deltek, Procare, DAT, and Neptune - as central to its decision. These same business-level difficulties had also weighed on the company’s third-quarter results, according to Oppenheimer.

InvestingPro data cited in the update indicates the stock’s relative strength index is in oversold territory, a technical signal that may allow for stabilization despite the operational headwinds. Nonetheless, Oppenheimer said it was concerned about the market’s confidence in Roper’s growth profile given the company’s recent guidance.

Management signaled expectations for improvement in the second half of the upcoming fiscal year, describing the anticipated recovery as "mechanical in nature." Management highlighted CentralReach and Subsplash as contributors to organic growth in the back half, aided in part by easier non-recurring comparisons versus the prior period.

Despite that outlook, Oppenheimer articulated a view that Roper needs to demonstrate high-single-digit organic growth to validate a higher valuation multiple. The firm said that achieving that growth target appears difficult in light of the present headwinds, and it trimmed its revenue and earnings-per-share estimates to reflect the less favorable outlook.

Oppenheimer also noted that Roper’s current valuation - roughly 17 times enterprise value to next twelve months free cash flow - may limit additional downside from a valuation standpoint. Still, the recalibration of forecasts and the rating change reflect diminished near-term expectations.

In separate corporate disclosures, Roper Technologies reported fourth-quarter 2025 results that were mixed. The company beat analysts’ estimates for earnings per share but fell short of revenue expectations. That divergence between EPS and top-line performance has drawn close attention from analysts and market observers and has formed part of a series of recent updates on the company’s financial performance.


Key takeaways

  • Oppenheimer downgraded Roper from Outperform to Perform and withdrew its price target after mixed Q4 results and disappointing FY26 guidance.
  • The research firm cited persistent headwinds at Deltek, Procare, DAT, and Neptune as primary drivers of the rating change.
  • Roper reported Q4 2025 EPS above estimates but missed revenue targets, prompting closer scrutiny from analysts and investors.

Risks and uncertainties

  • Execution risk tied to business-unit performance - continued weakness at Deltek, Procare, DAT, and Neptune could further pressure near-term results.
  • Investor confidence - Oppenheimer highlighted concerns that the market may remain skeptical until the company achieves higher organic growth.
  • Forecast revisions - lowered revenue and EPS estimates by Oppenheimer reflect uncertainty about the company’s ability to meet prior growth assumptions.

The downgrade and the mixed earnings print underscore a period of reassessment for Roper, with analysts watching whether the projected second-half improvements materialize and whether the company can restore a growth trajectory sufficient to support a premium valuation multiple.

Risks

  • Continued underperformance at specific business units (Deltek, Procare, DAT, Neptune) could further depress revenues and investor sentiment.
  • Weak investor confidence in Roper’s growth trajectory if the company cannot deliver high-single-digit organic growth to justify a higher valuation multiple.
  • Downward revisions to revenue and EPS estimates suggest near-term forecast risk and uncertainty about the timing and magnitude of any recovery.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026